955 related articles for article (PubMed ID: 28034291)
61. 110mIn-DTPA-D-Phe1-octreotide for imaging of neuroendocrine tumors with PET.
Lubberink M; Tolmachev V; Widström C; Bruskin A; Lundqvist H; Westlin JE
J Nucl Med; 2002 Oct; 43(10):1391-7. PubMed ID: 12368379
[TBL] [Abstract][Full Text] [Related]
62. Alternative and New Radiopharmaceutical Agents for Lung Cancer.
Telo S; Calderoni L; Vichi S; Zagni F; Castellucci P; Fanti S
Curr Radiopharm; 2020; 13(3):185-194. PubMed ID: 31868150
[TBL] [Abstract][Full Text] [Related]
63. Rapidly changing landscape of PET/CT imaging in prostate cancer.
Morigi JJ; Fanti S; Murphy D; Hofman MS
Curr Opin Urol; 2016 Sep; 26(5):493-500. PubMed ID: 27467137
[TBL] [Abstract][Full Text] [Related]
64. 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type.
Balogova S; Talbot JN; Nataf V; Michaud L; Huchet V; Kerrou K; Montravers F
Eur J Nucl Med Mol Imaging; 2013 Jun; 40(6):943-66. PubMed ID: 23417499
[TBL] [Abstract][Full Text] [Related]
65. Receptor radionuclide targeting for neuroendocrine tumors (NET) diagnostic and therapy.
Vija L; Dierickx L; Courbon F
Ann Endocrinol (Paris); 2019 Jun; 80(3):166-171. PubMed ID: 31053248
[TBL] [Abstract][Full Text] [Related]
66. Radio-guided surgery in neuroendocrine tumors.
Gulec SA; Baum R
J Surg Oncol; 2007 Sep; 96(4):309-15. PubMed ID: 17726664
[TBL] [Abstract][Full Text] [Related]
67. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors.
Frilling A; Sotiropoulos GC; Radtke A; Malago M; Bockisch A; Kuehl H; Li J; Broelsch CE
Ann Surg; 2010 Nov; 252(5):850-6. PubMed ID: 21037441
[TBL] [Abstract][Full Text] [Related]
68. Somatostatin Receptor Imaging PET in Neuroendocrine Neoplasm.
Johnbeck CB; Mortensen J
PET Clin; 2021 Apr; 16(2):191-203. PubMed ID: 33648664
[TBL] [Abstract][Full Text] [Related]
69. Peptide receptor radionuclide therapy with somatostatin analogues in neuroendocrine tumors.
Giovacchini G; Nicolas G; Forrer F
Anticancer Agents Med Chem; 2012 Jun; 12(5):526-42. PubMed ID: 22292758
[TBL] [Abstract][Full Text] [Related]
70. Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach.
Werner RA; Weich A; Higuchi T; Schmid JS; Schirbel A; Lassmann M; Wild V; Rudelius M; Kudlich T; Herrmann K; Scheurlen M; Buck AK; Kropf S; Wester HJ; Lapa C
Theranostics; 2017; 7(6):1489-1498. PubMed ID: 28529632
[TBL] [Abstract][Full Text] [Related]
71. Future Imaging of Prostate Cancer: Do We Need More Than PSMA PET/CT?
Vetrone L; Fortunati E; Castellucci P; Fanti S
Semin Nucl Med; 2024 Jan; 54(1):150-162. PubMed ID: 37394289
[TBL] [Abstract][Full Text] [Related]
72. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
[TBL] [Abstract][Full Text] [Related]
73. Imaging of neuroendocrine tumours with gamma-emitting radiopharmaceuticals.
Bombardieri E; Coliva A; Maccauro M; Seregni E; Orunesu E; Chiti A; Lucignani G
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):3-15. PubMed ID: 20168282
[TBL] [Abstract][Full Text] [Related]
74. Quantitative SPECT/CT for Dosimetry of Peptide Receptor Radionuclide Therapy.
Kennedy J; Chicheportiche A; Keidar Z
Semin Nucl Med; 2022 Mar; 52(2):229-242. PubMed ID: 34911637
[TBL] [Abstract][Full Text] [Related]
75. Dosimetry and first clinical evaluation of the new 18F-radiolabeled bombesin analogue BAY 864367 in patients with prostate cancer.
Sah BR; Burger IA; Schibli R; Friebe M; Dinkelborg L; Graham K; Borkowski S; Bacher-Stier C; Valencia R; Srinivasan A; Hany TF; Mu L; Wild PJ; Schaefer NG
J Nucl Med; 2015 Mar; 56(3):372-8. PubMed ID: 25678494
[TBL] [Abstract][Full Text] [Related]
76. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
Béhé M; Behr TM
Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
[TBL] [Abstract][Full Text] [Related]
77. Nuclear imaging of prostate cancer with gastrin-releasing-peptide-receptor targeted radiopharmaceuticals.
Ananias HJ; de Jong IJ; Dierckx RA; van de Wiele C; Helfrich W; Elsinga PH
Curr Pharm Des; 2008; 14(28):3033-47. PubMed ID: 18991717
[TBL] [Abstract][Full Text] [Related]
78. GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68Ga-labeled bombesin(6-14) analog.
Schuhmacher J; Zhang H; Doll J; Mäcke HR; Matys R; Hauser H; Henze M; Haberkorn U; Eisenhut M
J Nucl Med; 2005 Apr; 46(4):691-9. PubMed ID: 15809493
[TBL] [Abstract][Full Text] [Related]
79. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
[TBL] [Abstract][Full Text] [Related]
80. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues.
De Jong M; Breeman WA; Bernard HF; Kooij PP; Slooter GD; Van Eijck CH; Kwekkeboom DJ; Valkema R; Mäcke HR; Krenning EP
Q J Nucl Med; 1999 Dec; 43(4):356-66. PubMed ID: 10731786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
